ISSN: 1859 - 2872
Direct medical cost of thalassemia at Hochiminh Blood Transfusion and Hematology Hospital in 2023
Main Article Content
Keywords
Abstract
Objective: This study aims to analyze the direct medical cost incurred for outpatient care of Thalassemia at the Blood Transfusion and Hematology Hospital in Ho Chi Minh City in 2023 and to compare these expenditures among various groups of patients based on their characteristics. Subject and method: A retrospective analysis was conducted on the medical records of 100 outpatients who possessed health insurance and received treatment at the Department of Examination, Blood Transfusion and Hematology Hospital from January to September 2023. Result: The total direct medical cost covered by health insurance for Thalassemia outpatients is 62.04%. Drugs, tests, and blood are the three largest components of direct medical costs, accounting for 46.27%, 21.98%, and 20.98%, respectively. There is a statistically significant difference (p-value < 0.05) between the disease type and the severity of the patient’s disease in terms of direct treatment costs. Conclusion: The average direct cost per Alpha Thalassemia outpatient is 3,170,047 ± 1,374,217 VND and Beta Thalassemia is 7,343,727 ± 6,459,426 VND, with health insurance covering 62.04% and the patient covering 37.96%. This financial burden is significant for the patient and their family. Health insurance should consider increasing limits and reviewing payment lists to reduce this burden.
Article Details
References
2. Nguyễn Thị Thu Hà, Nguyễn Triệu Vân và cộng sự (2020) Tổng quan Thalassemia, thực trạng, nguy cơ và giải pháp kiểm soát bệnh Thalassemia ở Việt Nam. Tạp chí Y học Việt Nam.
3. Bộ Y tế (2022) Quyết định số 1832/QĐ-BYT về việc ban hành tài liệu chuyên môn “Hướng dẫn chẩn đoán và điều trị một số bệnh lý huyết học”.
4. Bộ Y tế (2018) Việt Nam hiện có trên 12 triệu người mang gen bệnh tan máu bẩm sinh truy cập ngày-05/08/2023, tại trang web https://moh.gov.vn/tin-lien-quan/-/asset_publisher/vjYyM7O9aWnX/content/viet-nam-hien-co-tren-12-trieu-nguoi-mang-gen-benh-tan-mau-bam-sinh.
5. Maria-Domenica Cappellini, Alan Cohen et al (2014) Guidelines for the management of transfusion dependent thalassaemia (TDT).
6. Maria-Domenica Cappellini, Alan Cohen et al (2008) Guidelines for the clinical management of thalassemia. Thalassaemia International Federation (TIF) April 2000.
7. Ali Taher, Elliott Vichinsky et al (2014) Guidelines for the management of non transfusion dependent thalassaemia (NTDT).
8. Taher A, El-Beshlawy A et al (2009) Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 82(6): 458-465.
9. Viprakasit V, Nuchprayoon I et al (2013) Deferiprone (GPO-L-ONE(®)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol 88(4): 251-60.
10. Wu SF, Peng CT et al (2006) Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin 30(2): 215-218.
Article Sidebar
